Loading
A phase 1/2 trial of Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Synthekine, now recruiting.
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers is a phase 1/2 interventional study registered as NCT05098132 by Synthekine, with 364 participants planned, started 2022-01-25 and due to reach its primary completion in 2029-01. Interventions recorded: STK-012, pembrolizumab KEYTRUDA®, pemetrexed, carboplatin. Conditions listed: Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/